Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions.

Abellanas MA, Zamarbide M, Basurco L, Luquin E, Garcia-Granero M, Clavero P, San Martin-Uriz P, Vilas A, Mengual E, Hervas-Stubbs S, Aymerich MS.

J Neuroinflammation. 2019 Nov 22;16(1):233. doi: 10.1186/s12974-019-1628-8.

2.

Dopamine Receptor D3 Expression Is Altered in CD4+ T-Cells From Parkinson's Disease Patients and Its Pharmacologic Inhibition Attenuates the Motor Impairment in a Mouse Model.

Elgueta D, Contreras F, Prado C, Montoya A, Ugalde V, Chovar O, Villagra R, Henríquez C, Abellanas MA, Aymerich MS, Franco R, Pacheco R.

Front Immunol. 2019 May 1;10:981. doi: 10.3389/fimmu.2019.00981. eCollection 2019.

3.

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.

Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J.

Biochem Pharmacol. 2018 Nov;157:67-84. doi: 10.1016/j.bcp.2018.08.016. Epub 2018 Aug 17. Review.

4.

The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.

Rojo-Bustamante E, Abellanas MA, Clavero P, Thiolat ML, Li Q, Luquin MR, Bezard E, Aymerich MS.

Neurobiol Dis. 2018 Oct;118:64-75. doi: 10.1016/j.nbd.2018.06.019. Epub 2018 Jun 21.

PMID:
29936234
5.

Stereological Estimates of Glutamatergic, GABAergic, and Cholinergic Neurons in the Pedunculopontine and Laterodorsal Tegmental Nuclei in the Rat.

Luquin E, Huerta I, Aymerich MS, Mengual E.

Front Neuroanat. 2018 May 11;12:34. doi: 10.3389/fnana.2018.00034. eCollection 2018.

6.

Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples.

Ugarte A, Corbacho D, Aymerich MS, García-Osta A, Cuadrado-Tejedor M, Oyarzabal J.

Neurotherapeutics. 2018 Jul;15(3):742-750. doi: 10.1007/s13311-018-0624-5.

7.

GPR55: A therapeutic target for Parkinson's disease?

Celorrio M, Rojo-Bustamante E, Fernández-Suárez D, Sáez E, Estella-Hermoso de Mendoza A, Müller CE, Ramírez MJ, Oyarzábal J, Franco R, Aymerich MS.

Neuropharmacology. 2017 Oct;125:319-332. doi: 10.1016/j.neuropharm.2017.08.017. Epub 2017 Aug 12.

PMID:
28807673
8.

Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.

Elgueta D, Aymerich MS, Contreras F, Montoya A, Celorrio M, Rojo-Bustamante E, Riquelme E, González H, Vásquez M, Franco R, Pacheco R.

Neuropharmacology. 2017 Feb;113(Pt A):110-123. doi: 10.1016/j.neuropharm.2016.09.028. Epub 2016 Sep 28.

PMID:
27693549
9.

Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Silveira MM, Arnold JC, Laviolette SR, Hillard CJ, Celorrio M, Aymerich MS, Adams WK.

Neurosci Biobehav Rev. 2017 May;76(Pt B):380-395. doi: 10.1016/j.neubiorev.2016.09.007. Epub 2016 Sep 14. Review.

10.

Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease.

Celorrio M, Fernández-Suárez D, Rojo-Bustamante E, Echeverry-Alzate V, Ramírez MJ, Hillard CJ, López-Moreno JA, Maldonado R, Oyarzábal J, Franco R, Aymerich MS.

Brain Behav Immun. 2016 Oct;57:94-105. doi: 10.1016/j.bbi.2016.06.010. Epub 2016 Jun 16.

PMID:
27318096
11.

Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins.

Cordomí A, Navarro G, Aymerich MS, Franco R.

Trends Biochem Sci. 2015 Oct;40(10):548-551. doi: 10.1016/j.tibs.2015.07.007.

12.

Neuroprotective Effect of JZL184 in MPP(+)-Treated SH-SY5Y Cells Through CB2 Receptors.

Aymerich MS, Rojo-Bustamante E, Molina C, Celorrio M, Sánchez-Arias JA, Franco R.

Mol Neurobiol. 2016 May;53(4):2312-9. doi: 10.1007/s12035-015-9213-3. Epub 2015 May 15.

PMID:
25976369
13.

Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model.

Fernández-Suárez D, Celorrio M, Riezu-Boj JI, Ugarte A, Pacheco R, González H, Oyarzabal J, Hillard CJ, Franco R, Aymerich MS.

Neurobiol Aging. 2014 Nov;35(11):2603-2616. doi: 10.1016/j.neurobiolaging.2014.05.021. Epub 2014 May 28.

PMID:
24973119
14.

GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells.

Zamarbide M, Etayo-Labiano I, Ricobaraza A, Martínez-Pinilla E, Aymerich MS, Luis Lanciego J, Pérez-Mediavilla A, Franco R.

Hippocampus. 2014 Jul;24(7):733-9. doi: 10.1002/hipo.22263. Epub 2014 Feb 27.

PMID:
24550142
15.

Loss of parvalbumin-positive neurons from the globus pallidus in animal models of Parkinson disease.

Fernández-Suárez D, Celorrio M, Lanciego JL, Franco R, Aymerich MS.

J Neuropathol Exp Neurol. 2012 Nov;71(11):973-82. doi: 10.1097/NEN.0b013e3182717cba.

PMID:
23044920
16.

A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system.

Ansorena E, Casales E, Aranda A, Tamayo E, Garbayo E, Smerdou C, Blanco-Prieto MJ, Aymerich MS.

Int J Pharm. 2013 Jan 2;440(1):19-26. doi: 10.1016/j.ijpharm.2012.04.071. Epub 2012 May 1.

17.

Real-time G-protein-coupled receptor imaging to understand and quantify receptor dynamics.

Aymerich MS, López-Azcárate J, Bonaventura J, Navarro G, Fernández-Suárez D, Casadó V, Mayor F, Lluís C, Valencia M, Artieda J, Franco R.

ScientificWorldJournal. 2011;11:1995-2010. doi: 10.1100/2011/690858. Epub 2011 Oct 26.

18.

Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease.

Garbayo E, Ansorena E, Lanciego JL, Blanco-Prieto MJ, Aymerich MS.

Mov Disord. 2011 Aug 15;26(10):1943-7. doi: 10.1002/mds.23793. Epub 2011 Jun 9.

PMID:
21661048
19.

Cocaine self-administration markedly increases dopamine D2 receptor negative cooperativity for dopamine binding: A receptor dimer-based analysis.

Franco R, Seeman P, Barrera C, Aymerich MS.

Synapse. 2010 Jul;64(7):566-9. doi: 10.1002/syn.20775.

PMID:
20336632
20.

Two-color fluorescence labeling in acrolein-fixed brain tissue.

Luquin E, Pérez-Lorenzo E, Aymerich MS, Mengual E.

J Histochem Cytochem. 2010 Apr;58(4):359-68. doi: 10.1369/jhc.2009.954495. Epub 2010 Jan 4.

21.

Production of highly pure human glycosylated GDNF in a mammalian cell line.

Ansorena E, Garbayo E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

Int J Pharm. 2010 Jan 29;385(1-2):6-11. doi: 10.1016/j.ijpharm.2009.10.015. Epub 2009 Oct 13.

22.

Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors.

Navarro G, Aymerich MS, Marcellino D, Cortés A, Casadó V, Mallol J, Canela EI, Agnati L, Woods AS, Fuxe K, Lluís C, Lanciego JL, Ferré S, Franco R.

J Biol Chem. 2009 Oct 9;284(41):28058-68. doi: 10.1074/jbc.M109.034231. Epub 2009 Jul 24.

23.

Effective GDNF brain delivery using microspheres--a promising strategy for Parkinson's disease.

Garbayo E, Montero-Menei CN, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

J Control Release. 2009 Apr 17;135(2):119-26. doi: 10.1016/j.jconrel.2008.12.010. Epub 2008 Dec 25.

24.

The search for a role of the caudal intralaminar nuclei in the pathophysiology of Parkinson's disease.

Lanciego JL, López IP, Rico AJ, Aymerich MS, Pérez-Manso M, Conte L, Combarro C, Roda E, Molina C, Gonzalo N, Castle M, Tuñón T, Erro E, Barroso-Chinea P.

Brain Res Bull. 2009 Feb 16;78(2-3):55-9. doi: 10.1016/j.brainresbull.2008.08.008. Epub 2008 Nov 12. Review.

PMID:
18790023
25.

Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres.

Garbayo E, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

Eur J Pharm Biopharm. 2008 Aug;69(3):844-51. doi: 10.1016/j.ejpb.2008.02.015. Epub 2008 Feb 23.

26.

Expression of vesicular glutamate transporters 1 and 2 in the cells of origin of the rat thalamostriatal pathway.

Barroso-Chinea P, Castle M, Aymerich MS, Lanciego JL.

J Chem Neuroanat. 2008 Jan;35(1):101-7. Epub 2007 Aug 8.

PMID:
17826944
27.

Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor.

Garbayo E, Ansorena E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ.

Int J Pharm. 2007 Nov 1;344(1-2):9-15. Epub 2007 Apr 6.

28.

Detection of two different mRNAs in a single section by dual in situ hybridization: a comparison between colorimetric and fluorescent detection.

Barroso-Chinea P, Aymerich MS, Castle MM, Pérez-Manso M, Tuñón T, Erro E, Lanciego JL.

J Neurosci Methods. 2007 May 15;162(1-2):119-28. Epub 2007 Jan 12.

29.

Expression of the mRNAs encoding for the vesicular glutamate transporters 1 and 2 in the rat thalamus.

Barroso-Chinea P, Castle M, Aymerich MS, Pérez-Manso M, Erro E, Tuñon T, Lanciego JL.

J Comp Neurol. 2007 Apr 10;501(5):703-15.

30.

[Neuroprotective and neurorestorative therapies for the treatment of Parkinson's disease].

Garbayo E, Aymerich MS, Ansorena E, Lanciego JL, Blanco-Prieto MJ.

An Sist Sanit Navar. 2006 Sep-Dec;29(3):325-35. Review. Spanish.

31.

Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats.

Aymerich MS, Barroso-Chinea P, Pérez-Manso M, Muñoz-Patiño AM, Moreno-Igoa M, González-Hernández T, Lanciego JL.

Eur J Neurosci. 2006 Apr;23(8):2099-108.

32.

'Functional' neuroanatomical tract tracing: analysis of changes in gene expression of brain circuits of interest.

Pérez-Manso M, Barroso-Chinea P, Aymerich MS, Lanciego JL.

Brain Res. 2006 Feb 9;1072(1):91-8. Epub 2006 Jan 19.

PMID:
16423326
33.

Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer.

Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, Shroff EH, Volpert OV.

Cancer Res. 2005 Jun 15;65(12):5144-52.

34.

Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells.

Barroso-Chinea P, Cruz-Muros I, Aymerich MS, Rodríguez-Díaz M, Afonso-Oramas D, Lanciego JL, González-Hernández T.

Eur J Neurosci. 2005 Apr;21(7):1815-27.

PMID:
15869477
35.

Thalamic innervation of the direct and indirect basal ganglia pathways in the rat: Ipsi- and contralateral projections.

Castle M, Aymerich MS, Sanchez-Escobar C, Gonzalo N, Obeso JA, Lanciego JL.

J Comp Neurol. 2005 Mar 7;483(2):143-53.

36.

Thalamic innervation of striatal and subthalamic neurons projecting to the rat entopeduncular nucleus.

Lanciego JL, Gonzalo N, Castle M, Sanchez-Escobar C, Aymerich MS, Obeso JA.

Eur J Neurosci. 2004 Mar;19(5):1267-77.

37.

Identification of the neuroprotective molecular region of pigment epithelium-derived factor and its binding sites on motor neurons.

Bilak MM, Becerra SP, Vincent AM, Moss BH, Aymerich MS, Kuncl RW.

J Neurosci. 2002 Nov 1;22(21):9378-86.

38.

Evidence for pigment epithelium-derived factor receptors in the neural retina.

Aymerich MS, Alberdi EM, Martínez A, Becerra SP.

Invest Ophthalmol Vis Sci. 2001 Dec;42(13):3287-93.

PMID:
11726635
39.
40.

Inducible nitric oxide synthase (iNOS) expression in human monocytes triggered by beta-endorphin through an increase in cAMP.

Aymerich MS, Bengoechea-Alonso MT, López-Zabalza MJ, Santiago E, López-Moratalla N.

Biochem Biophys Res Commun. 1998 Apr 28;245(3):717-21.

PMID:
9588181
41.

Monocyte inducible nitric oxide synthase in multiple sclerosis: regulatory role of nitric oxide.

López-Moratalla N, González A, Aymerich MS, López-Zabalza MJ, Pío R, de Castro P, Santiago E.

Nitric Oxide. 1997 Feb;1(1):95-104.

PMID:
9701049
42.

Inducible nitric oxide synthase in monocytes from patients with Graves' disease.

López-Moratalla N, Calleja A, González A, Pérez-Mediavilla LA, Aymerich MS, Burrel MA, Santiago E.

Biochem Biophys Res Commun. 1996 Sep 24;226(3):723-9.

Supplemental Content

Loading ...
Support Center